U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.

BACKGROUND The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into the U.S. childhood immunization schedule in 2000 has substantially reduced the incidence of vaccine-serotype invasive pneumococcal disease in young children and in unvaccinated older children and adults. By 2004, hospitalizations associated with pneumonia from any cause had also declined markedly among young children. Because of concerns about increases in disease caused by nonvaccine serotypes, we wanted to determine whether the reduction in pneumonia-related hospitalizations among young children had been sustained through 2009 and whether such hospitalizations in older age groups had also declined. METHODS We estimated annual rates of hospitalization for pneumonia from any cause using the Nationwide Inpatient Sample database. The reason for hospitalization was classified as pneumonia if pneumonia was the first listed diagnosis or if it was listed after a first diagnosis of sepsis, meningitis, or empyema. Average annual rates of pneumonia-related hospitalizations from 1997 through 1999 (before the introduction of PCV7) and from 2007 through 2009 (well after its introduction) were used to estimate annual declines in hospitalizations due to pneumonia. RESULTS The annual rate of hospitalization for pneumonia among children younger than 2 years of age declined by 551.1 per 100,000 children (95% confidence interval [CI], 445.1 to 657.1), which translates to 47,000 fewer hospitalizations annually than expected on the basis of the rates before PCV7 was introduced. The rate for adults 85 years of age or older declined by 1300.8 per 100,000 (95% CI, 984.0 to 1617.6), which translates to 73,000 fewer hospitalizations annually. For the three age groups of 18 to 39 years, 65 to 74 years, and 75 to 84 years, the annual rate of hospitalization for pneumonia declined by 8.4 per 100,000 (95% CI, 0.6 to 16.2), 85.3 per 100,000 (95% CI, 7.0 to 163.6), and 359.8 per 100,000 (95% CI, 199.6 to 520.0), respectively. Overall, we estimated an age-adjusted annual reduction of 54.8 per 100,000 (95% CI, 41.0 to 68.5), or 168,000 fewer hospitalizations for pneumonia annually. CONCLUSIONS Declines in hospitalizations for childhood pneumonia were sustained during the decade after the introduction of PCV7. Substantial reductions in hospitalizations for pneumonia among adults were also observed. (Funded by the Centers for Disease Control and Prevention.).

[1]  能登 洋 The New England Journal of Medicine (NEJM) サイトの活用 (特集 図書館の活用の広がり) , 2015 .

[2]  W. Schaffner,et al.  Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  C. Whitney,et al.  Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2013, MMWR. Morbidity and mortality weekly report.

[4]  D. Musher Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Peter K Lindenauer,et al.  Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003-2009. , 2012, JAMA.

[6]  M. Lipsitch,et al.  Pneumococcal Carriage and Antibiotic Resistance in Young Children Before 13-valent Conjugate Vaccine , 2012, The Pediatric infectious disease journal.

[7]  W. Lim,et al.  Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia , 2012, Thorax.

[8]  E. Shapiro Prevention of pneumococcal infection with vaccines: an evolving story. , 2012, JAMA.

[9]  M. Lipsitch,et al.  Serotype replacement in disease after pneumococcal vaccination , 2011, The Lancet.

[10]  W. Schaffner,et al.  Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Bartlett Diagnostic tests for agents of community-acquired pneumonia. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Robert J. Taylor,et al.  Impact of Pneumococcal Conjugate Vaccination of Infants on Pneumonia and Influenza Hospitalization and Mortality in All Age Groups in the United States , 2011, mBio.

[13]  W. Schaffner,et al.  Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization , 2010, AIDS.

[14]  S. Saxena,et al.  Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997–2008 , 2010, Thorax.

[15]  P. McIntyre,et al.  Reduction in Hospitalizations for Pneumonia Associated With the Introduction of a Pneumococcal Conjugate Vaccination Schedule Without a Booster Dose in Australia , 2010, The Pediatric infectious disease journal.

[16]  Yuwei Zhu,et al.  Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Molyneux,et al.  A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. , 2010, The New England journal of medicine.

[18]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[19]  Carlos G. Grijalva,et al.  Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. , 2009, JAMA.

[20]  M. Lipsitch,et al.  Continued Impact of Pneumococcal Conjugate Vaccine on Carriage in Young Children , 2009, Pediatrics.

[21]  K. O'Brien Pneumococcal vaccine and the dance of the veils: revealing pneumonia burden in Asia. , 2009, The Pediatric infectious disease journal.

[22]  Carlos G. Grijalva,et al.  Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine - United States, 1997-2006. , 2009 .

[23]  J. Stockman Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis , 2009 .

[24]  A. Fiore,et al.  Influenza vaccination coverage among children aged 6 months--18 years - eight immunization information system sentinel sites, United States, 2008-09 influenza season. , 2009, MMWR. Morbidity and mortality weekly report.

[25]  A. Shefer,et al.  Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. , 2007, Archives of pediatrics & adolescent medicine.

[26]  L. Hammitt,et al.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. , 2007, JAMA.

[27]  Roger I Glass,et al.  Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[28]  K. Auranen,et al.  Nasopharyngeal colonization: a target for pneumococcal vaccination , 2006, Expert review of vaccines.

[29]  T. Cherian,et al.  Effectiveness of Heptavalent Pneumococcal Conjugate Vaccine in Children Younger Than 5 Years of Age for Prevention of Pneumonia: Updated Analysis Using World Health Organization Standardized Interpretation of Chest Radiographs , 2006, The Pediatric infectious disease journal.

[30]  K. Poehling,et al.  National Impact of Universal Childhood Immunization With Pneumococcal Conjugate Vaccine on Outpatient Medical Care Visits in the United States , 2006, Pediatrics.

[31]  L. Hammitt,et al.  Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. , 2006, The Journal of infectious diseases.

[32]  R. Holman,et al.  Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. , 2005, JAMA.

[33]  A. Schuchat,et al.  Increased prevalence of pediatric pneumococcal serotypes in elderly adults. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  S. Pelton,et al.  Seven Valent Pneumococcal Conjugate Vaccine Immunization in Two Boston Communities: Changes in Serotypes and Antimicrobial Susceptibility Among Streptococcus pneumoniae Isolates , 2004, The Pediatric infectious disease journal.

[35]  B. LaFleur,et al.  Population-Based Impact of Pneumococcal Conjugate Vaccine in Young Children , 2004, Pediatrics.

[36]  A. Schuchat,et al.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.

[37]  K. Klugman Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. , 2001, The Lancet. Infectious diseases.